The NIFTY™ test is a non-invasive prenatal test (commonly termed an NIPT) that screens for Down Syndrome and certain other genetic conditions caused by extra or missing genetic information in the baby’s DNA.
To date The NIFTY™ has succesfully issued more than 3,500,000 results making it not only the worlds first NIPT historically, but an absolute global leader in volume of processed samples. NIFTY™ is NIPT No. 1 worldwide.
In 2016, after 5 years of building Recombine, a leading company in reproductive genetics, Alexander Bisignano and Santiago Munne, together with a team of computer scientists, engineers, and geneticists, founded Phosphorus to address the larger issues preventing genomics from more widely improving the healthcare ecosystem. By enabling adoption of advanced genetic testing in partner laboratories around the world, Phosphorus is building a distributed genomic data network that will help providers, researchers, and patients better understand and harness the power of the human genome.
SENTIS™ is a comprehensive screening test for hereditary breast and ovarian cancers.
SENTIS™ as a Hereditary Breast and Ovarian (HBOC) panel provides health providers and patients with information on 21 genes associated with Hereditary Breast and Ovarian Cancer (HBOC) based on recent scientific and clinical literature. SENTIS™ detects different alterations including germline SNV, Indels and CNV.